172 related articles for article (PubMed ID: 38128117)
21. Menopausal hormone therapy and risk of seropositive rheumatoid arthritis: A nationwide cohort study in Korea.
Yuk JS; Seo YS; Im YH; Kim JH
Semin Arthritis Rheum; 2023 Dec; 63():152280. PubMed ID: 37857046
[TBL] [Abstract][Full Text] [Related]
22. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz GA; Hankinson SE; Hunter DJ; Willett WC; Manson JE; Stampfer MJ; Hennekens C; Rosner B; Speizer FE
N Engl J Med; 1995 Jun; 332(24):1589-93. PubMed ID: 7753136
[TBL] [Abstract][Full Text] [Related]
23. [Clinical evaluation of progestogens used in Menopausal Hormone Therapy (MHT)].
Mueck AO
Ther Umsch; 2021; 78(8):447-455. PubMed ID: 34555976
[TBL] [Abstract][Full Text] [Related]
24. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.
Schairer C; Lubin J; Troisi R; Sturgeon S; Brinton L; Hoover R
JAMA; 2000 Jan; 283(4):485-91. PubMed ID: 10659874
[TBL] [Abstract][Full Text] [Related]
25. Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort.
Wang SM; Pfeiffer RM; Gierach GL; Falk RT
Breast Cancer Res; 2020 Nov; 22(1):129. PubMed ID: 33239054
[TBL] [Abstract][Full Text] [Related]
26. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
van Leeuwen FE
Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
[TBL] [Abstract][Full Text] [Related]
27. Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study.
Cold S; Cold F; Jensen MB; Cronin-Fenton D; Christiansen P; Ejlertsen B
J Natl Cancer Inst; 2022 Oct; 114(10):1347-1354. PubMed ID: 35854422
[TBL] [Abstract][Full Text] [Related]
28. Menopausal hormone therapy and breast cancer.
Santen RJ
J Steroid Biochem Mol Biol; 2014 Jul; 142():52-61. PubMed ID: 23871991
[TBL] [Abstract][Full Text] [Related]
29. [Menopause and risk of thromboembolic events. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines].
Hugon-Rodin J; Perol S; Plu-Bureau G
Gynecol Obstet Fertil Senol; 2021 May; 49(5):455-461. PubMed ID: 33757918
[TBL] [Abstract][Full Text] [Related]
30. Prediagnostic use of estrogen-only therapy is associated with improved colorectal cancer survival in menopausal women: a Swedish population-based cohort study.
Simin J; Liu Q; Wang X; Fall K; Williams C; Callens S; Engstrand L; Brusselaers N
Acta Oncol; 2021 Jul; 60(7):881-887. PubMed ID: 33861686
[TBL] [Abstract][Full Text] [Related]
31. Skin cancer risk of menopausal hormone therapy in a Korean cohort.
Yuk JS; Lee SK; Uh JA; Seo YS; Kim M; Kim MS
Sci Rep; 2023 Jun; 13(1):10572. PubMed ID: 37386069
[TBL] [Abstract][Full Text] [Related]
32. Menopausal hormone therapy with conjugated equine estrogen is associated with a higher risk of hemorrhagic stroke than therapy with estradiol: a retrospective population-based cohort study.
Chang WC; Wang JH; Ding DC
Maturitas; 2022 Nov; 165():72-77. PubMed ID: 35933795
[TBL] [Abstract][Full Text] [Related]
33. Changing concepts: Menopausal hormone therapy and breast cancer.
Chlebowski RT; Anderson GL
J Natl Cancer Inst; 2012 Apr; 104(7):517-27. PubMed ID: 22427684
[TBL] [Abstract][Full Text] [Related]
34. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women.
Stanford JL; Weiss NS; Voigt LF; Daling JR; Habel LA; Rossing MA
JAMA; 1995 Jul; 274(2):137-42. PubMed ID: 7596001
[TBL] [Abstract][Full Text] [Related]
35. [Menopausal hormonal therapy and breast cancer.].
Bakhidze EV; Belyaeva AV; Berlev IV; Anisimov VN; Belyaev AM
Adv Gerontol; 2021; 34(2):277-286. PubMed ID: 34245512
[TBL] [Abstract][Full Text] [Related]
36. Effects of menopausal hormone therapy on cardiovascular diseases and type 2 diabetes in middle-aged postmenopausal women: analysis of the Korea National Health Insurance Service Database.
Kim JE; Choi J; Park J; Shin A; Choi NK; Choi JY
Menopause; 2021 Sep; 28(11):1225-1232. PubMed ID: 34520413
[TBL] [Abstract][Full Text] [Related]
37. Different menopausal hormone regimens and risk of breast cancer.
Brusselaers N; Tamimi RM; Konings P; Rosner B; Adami HO; Lagergren J
Ann Oncol; 2018 Aug; 29(8):1771-1776. PubMed ID: 29917061
[TBL] [Abstract][Full Text] [Related]
38. Relationship between the type of hormone replacement therapy and incidence of breast cancer in Korea.
Baek JK; Kim HI; Kang MJ; Seon KE; Kim EH; Seo SK
Climacteric; 2022 Oct; 25(5):516-522. PubMed ID: 35674251
[TBL] [Abstract][Full Text] [Related]
39. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States).
Schairer C; Byrne C; Keyl PM; Brinton LA; Sturgeon SR; Hoover RN
Cancer Causes Control; 1994 Nov; 5(6):491-500. PubMed ID: 7827235
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of menopausal hormone therapy use in Korea (2002-2013): A nationwide cohort study.
Park CY; Lim JY; Kim WH; Kim SY; Park HY
Maturitas; 2021 Apr; 146():57-62. PubMed ID: 33722365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
